Skip to main content
. 2016 Jan 8;6(1):e378. doi: 10.1038/bcj.2015.96

Table 2. Patient disposition.

Characteristic, n (%) Zoledronic acid (n=93) Denosumab (n=87)
Withdrew before primary data cutoff 45 (48%) 48 (55%)
 Death 8 (9%) 19 (22%)
 Consent withdrawn 16 (17%) 11 (13%)
 Other 3 (3%) 6 (7%)
 Disease progression 1 (1%) 6 (7%)
 Subject request 6 (7%) 3 (3%)
 Adverse event 7 (8%) 2 (3%)
 Protocol deviation 0 (0%) 1 (1%)
 Noncompliance 2 (2%) 0 (0%)
 Ineligibility determined 1 (1%) 0 (0%)
 Lost to follow-up 1 (1%) 0 (0%)